A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Clinical trial NCT07375316 · RECRUITING
Trial details
- NCT number
- NCT07375316
- Sponsor
- Guangdong Association of Clinical Trials
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-15
- Primary completion
- 2028-06-30
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.